Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Remedies

HOPE Welcomes Autism Bill's Progress Following First Reading In The Lords, UK
HOPE, the charity for adults with autism and learning
generic viagra online
Doctor And Nurse Shortages Plague U.S.
The nation"s struggles with physician and nurse shortages are evident as health care reform takes shape.
News of the day
DNA Template Could Explain Evolutionary Shifts
Rearrangements of all sizes in genomes, genes and exons can result from a glitch in DNA copying that occurs when the process stalls at a critical point and then shifts to a different genetic template, duplicating and even triplicating genes or just shuffling or deleting part of the code within them, said researchers from Baylor College of Medicine in a recent report in the journal Nature Genetics. The report further elucidated the effect of the fork stalling and template switching mechanism involved in some forms of copy number variation.
Nutrition

St. Jude Medical Announces Leading Sponsorship Of Landmark Clinical Trial To Study Atrial Fibrillation

St. Jude Medical, Inc. (NYSE:STJ) today announced that it is the leading sponsor of the Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial. The pivotal trial, announced by Mayo Clinic, is intended to determine the effectiveness of catheter ablation (using long, narrow tubes to non-invasively reach and destroy abnormal heart tissue) in eliminating atrial fibrillation (AF), a condition in which the upper chambers of the heart beat quickly and erratically. "The results of the CABANA trial will be significant in shaping the future of cardiac ablation as a treatment and possible cure for AF," said Daniel J. Starks, Chairman, President and Chief Executive Officer of St. Jude Medical. "Supporting clinical trials like CABANA is an important part of our mission of advancing the practice of medicine through medical technology to help improve patient outcomes." The CABANA pivotal trial will last up to six years and will study the treatment of atrial fibrillation in a total of 3,000 patients and 140 centers from around the world. It will randomize patients over three years, with half undergoing catheter ablation and half receiving rate control or rhythm control drug therapy. Douglas Packer, M.D., a cardiologist at Mayo Clinic, will be the principal investigator of the clinical trial. Prior to the launch of this trial, Dr. Packer and Mayo Clinic led a 10-center, 60-patient pilot study. The results of this pilot study will be released later this summer. The CABANA Trial will be conducted in collaboration with the Heart Rhythm Service and Biomedical Imaging Res at Mayo Clinic, Rochester, Minn., Duke Clinical Research Institute, Durham, N.C., and CABANA Investigators. Mayo Clinic and Drs. Packer and Richard Robb, Ph.D., Mayo Clinic, have a financial interest in a mapping technology, licensed to St. Jude Medical, that may or may not be used in this research. St. Jude Medical


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009